Retatrutide is a new triple-action hormonal peptide that triggers unprecedented weight loss, surpassing previous generations of weight management molecules.

noli's read

Research confirms the impressive efficacy of this molecule called retatrutide, which acts as a 'triple-action' body messenger by stimulating satiety and energy expenditure hormones. Recent data from the large phase 3 clinical trial TRIUMPH-1 (conducted by Eli Lilly) confirms an average weight loss ranging from 28% to 30% over nearly two years. This high-level evidence is based on a randomized controlled trial (RCT), scientifically validating performance comparable to a physical stomach reduction. The creator remains measured and does not exaggerate the promise: they rightly mention common side effects (digestive sensitivity, slight transient increase in heart rate). Without suggesting exaggeration, it must simply be noted that the long-term safety data (beyond 104 weeks) has yet to be documented for this very recent molecule.

the sources

1. 1Wilding JPH et al. (STEP 1) 2021
2. 2Jastreboff AM et al. (SURMOUNT-1) 2022
3. 3Jastreboff AM et al. 2023
4. 4Wilding JPH et al. (STEP 1 extension) 2022